Angom et al.23 reported that patient-derived GBM cells expressing shRNAs of VEGF or NRP-1 attenuated CSC markers and inhibited the neurosphere-forming capacity and migration of tumor-initiating cells. The gene discussed is NRP1; the disease is neoplasm.